Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 16/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.83 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979191 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL28781069 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL4979182 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL5076337 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL5076339 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14529305 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL12796167 | 0.91 | CCR5 (0.83) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.88 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073315 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10083413 | 0.87 | CCR5 (0.83) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375444-A1 | METHOD OF TREATING ALZHEIMER’S DISEASE | AMYRIAD PHARMA INC (US) | 2025-12-11 | — | — | US | claimed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-120020252-A | SiRNA for inhibiting LPA expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-113584090-B | Biological preparation method of chemokine CCR 5 antagonist AD101 chiral intermediate | 浙江工业大学 | 2024-07-19 | — | — | CN | claimed |
| US-20240156812-A1 | METHOD OF TREATING ALZHEIMER’S DISEASE | AMYRIAD PHARMA, INC. | 2024-05-16 | — | — | US | claimed |
| EP-4340834-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE | Amyriad Pharma, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117529318-A | Methods of treating Alzheimer's disease | 阿米利亚德制药公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2022246059-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE | AMYRIAD PHARMA, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20220370443-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE | AMYRIAD PHARMA, INC. | 2022-11-24 | — | — | US | claimed |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CYTODYN INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375444-A1 | METHOD OF TREATING ALZHEIMER’S DISEASE | AMYRIAD PHARMA INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-3005942-B1 | Method for the detection and characterisation of bubbles in liquids and device therefor, resp.system | ARISTOTLE UNIV OF THESSALONIKI RESEARCH COMMITTEE (GR) | 2025-12-03 | — | — | EP | disclosed |
| US-12339313-B2 | Electrical testing method for semiconductor device | RENESAS ELECTRONICS CORPORATION (JP) | 2025-06-24 | — | — | US | disclosed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007098247-A2 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CCR5 1/4885CHRM2 117/4885CHRM1 165/4885 |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CCR5, CCL2, CCR2 | CCR5 1/4885CHRM2 1070/4885CHRM1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.